Tevogen Bio 8/19/2025 Earnings Report

Tevogen Bio EPS Results

• Actual EPS: -$1.50
• Consensus EPS: -$2.50
• Beat/Miss: Beat by +$1.00
• One Year Ago EPS: N/A

Tevogen Bio Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tevogen Bio Announcement Details

• Date: 8/19/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Tevogen Bio (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing precision T-cell therapies for patients with viral infections and cancer. The company’s approach uses antigen-specific cytotoxic T lymphocytes designed to recognize and eliminate infected or abnormal cells while seeking to provide an “off-the-shelf” treatment option.

Tevogen’s pipeline is built around its ExacTcell platform, which is intended to support the development and manufacturing of targeted cellular immunotherapies. Its lead program, TVGN 489, is an investigational, SARS-CoV-2-specific T-cell therapy being developed for immunocompromised patients who may remain vulnerable to COVID-19. The therapy is not approved for commercial use.

Tevogen was founded by physician and biotechnology executive Dr. Ryan Saadi, who serves as the company’s chairman and chief executive officer. The company is based in Warren, New Jersey, and is developing therapies for potential use in the United States and other markets, subject to clinical development and regulatory approvals. Tevogen became a publicly traded company through a business combination with Semper Paratus Acquisition Corporation.